Literature DB >> 7510888

Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice.

J Wu1, T Zhou, J Zhang, J He, W C Gause, J D Mountz.   

Abstract

MRL-lpr/lpr mice develop a generalized autoimmune disease which includes increased autoantibody production, glomerulonephritis, and development of lymphadenopathy. The lpr genetic defect has been identified as a mutation in the Fas apoptosis gene that results in low expression of Fas mRNA. To determine the significance of the lpr mutation and T cells in the development of the autoimmune disease, we constructed transgenic MRL-lpr/lpr mice using a full-length murine Fas cDNA under the regulation of the T-cell-specific CD2 promoter and enhancer. Here we show that the early correction of the lpr gene defect in T cells eliminates glomerulonephritis and development of lymphadenopathy and decreases the levels of autoantibodies. In this model, early correction of the lpr defect in T cells is sufficient to eliminate the acceleration of autoimmune disease even in the presence of B cells and other cells that express the mutant lpr gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510888      PMCID: PMC43367          DOI: 10.1073/pnas.91.6.2344

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Expression and ontogeny of CD2 on murine B cells.

Authors:  J Sen; N Rosenberg; S J Burakoff
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

2.  Altered expression of self-reactive T cell receptor V beta regions in autoimmune mice.

Authors:  J D Mountz; T M Smith; K S Toth
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

3.  Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells.

Authors:  H Yagita; T Nakamura; H Karasuyama; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 4.  Production of transgenic mice and application to immunology and autoimmunity.

Authors:  J D Mountz; T Zhou; L Johnson
Journal:  Am J Med Sci       Date:  1990-11       Impact factor: 2.378

5.  Human CD2 3'-flanking sequences confer high-level, T cell-specific, position-independent gene expression in transgenic mice.

Authors:  D R Greaves; F D Wilson; G Lang; D Kioussis
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

6.  CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.

Authors:  J D Mountz; H R Smith; R L Wilder; J P Reeves; A D Steinberg
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

7.  Evidence for an intrinsic B cell defect in lpr/lpr mice apparent in neonatal chimeras.

Authors:  D L Perkins; R M Glaser; C A Mahon; J Michaelson; A Marshak-Rothstein
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

8.  Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice.

Authors:  A D Steinberg; J B Roths; E D Murphy; R T Steinberg; E S Raveche
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

9.  Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.

Authors:  N L Carteron; C L Schimenti; D Wofsy
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

10.  Deletion of potentially self-reactive T cell receptor specificities in L3T4-, Lyt-2- T cells of lpr mice.

Authors:  B L Kotzin; S K Babcock; L R Herron
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Regulation of apoptosis in immune cells.

Authors:  J D Mountz; T Zhou; J Wu; W Wang; X Su; J Cheng
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

2.  Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.

Authors:  L B Owen-Schaub; W Zhang; J C Cusack; L S Angelo; S M Santee; T Fujiwara; J A Roth; A B Deisseroth; W W Zhang; E Kruzel
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

Review 3.  Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment?

Authors:  P E Spronk; H Bootsma; C G Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  A role for the Fas antigen in lupus?

Authors:  A K Singh
Journal:  Postgrad Med J       Date:  1996-01       Impact factor: 2.401

5.  CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease.

Authors:  K G Smith; A Strasser; D L Vaux
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

6.  Curing lupus--views from the foothills.

Authors:  J H Klippel
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

7.  Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM.

Authors:  C Giordano; R De Maria; G Stassi; M Todaro; P Richiusa; M Giordano; R Testi; A Galluzzo
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

8.  Localized immune tolerance from FasL-functionalized PLG scaffolds.

Authors:  Michael Skoumal; Kyle B Woodward; Hong Zhao; Feng Wang; Esma S Yolcu; Ryan M Pearson; Kevin R Hughes; Andrés J García; Lonnie D Shea; Haval Shirwan
Journal:  Biomaterials       Date:  2018-11-13       Impact factor: 12.479

9.  Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling.

Authors:  Pachiyappan Kamarajan; Nian-Kang Sun; Chuck C-K Chao
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

10.  Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.

Authors:  S Takahashi; L Fossati; M Iwamoto; R Merino; R Motta; T Kobayakawa; S Izui
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.